0.40
+0.0114(+2.92%)
Currency In USD
Address
900 Stewart Avenue
Garden City, NY 11530
United States of America
Phone
516 665 8200
Website
Sector
Healthcare
Industry
Medical - Devices
Employees
107
First IPO Date
June 12, 2018
| Name | Title | Pay | Year Born |
| Mr. Amir Avniel | Chief Executive Officer of NeuroNOS | 495,997 | 1974 |
| Mr. Steven Adam Lisi | Chief Executive Officer & Chairman of the Board | 650,000 | 1971 |
| Mr. Adam Newman | Corporate Secretary | 250,000 | N/A |
| Mr. Douglas Quinton Larson | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer | 274,955 | 1970 |
| Mr. Michael A. Gaul | Chief Operating Officer | 400,000 | 1955 |
| Mr. David R. Webster | Chief Commercial Officer | 0 | 1967 |
| Dr. John Jett Ph.D. | Head of Research & Clinical Development | 0 | N/A |
| Dr. Andrew R. Colin M.D. | Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory Board | 0 | N/A |
| Edward Barger | Head of Investor Relations | 0 | N/A |
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.